Bristol-Myers Squibb Company (BVMF:BMYB34)
Brazil · Delayed Price · Currency is BRL | Market Cap | 620.50B -11.9% |
| Revenue (ttm) | 265.45B -0.2% |
| Net Income | 38.85B |
| EPS | 19.06 |
| Shares Out | n/a |
| PE Ratio | 15.97 |
| Forward PE | 9.15 |
| Dividend | 8.97 (2.93%) |
| Ex-Dividend Date | Jan 2, 2026 |
| Volume | 10 |
| Average Volume | 149 |
| Open | 305.86 |
| Previous Close | 311.23 |
| Day's Range | 305.86 - 305.86 |
| 52-Week Range | 227.85 - 352.05 |
| Beta | 0.27 |
| RSI | 48.25 |
| Earnings Date | Apr 30, 2026 |
About BVMF:BMYB34
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company’s products include Opdivo for various anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumorsr; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Reblozyl to treat ... [Read more]
News
Bristol Myers Squibb Transforms the Classical Hodgkin Lymphoma Treatment Paradigm with Expanded U.S. and EMA Approvals for Opdivo® (nivolumab)
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CheckMate--Bristol Myers Squibb Transforms the Classical Hodgkin Lymphoma Treatment Paradigm with Expanded U.S. and EMA Approvals for Opdivo® (nivolumab).
Bristol Myers Secures FDA Nod For Opdivo Plus Chemo For Untreated Hodgkin Lymphoma
• Bristol-Myers Squibb shares are experiencing downward pressure. Why is BMY stock retreating?
US FDA approves Bristol Myers Squibb's cancer drug for Hodgkin's lymphoma
The U.S. Food and Drug Administration on Friday approved Bristol Myers Squibb's combination treatment for adults and adolescents aged 12 and older with previously untreated Stage III or ...
Bristol Myers Squibb to Report Results for First Quarter 2026 on April 30, 2026
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Report Results for First Quarter 2026 on April 30, 2026.
TrumpRx lists many medicines at prices higher than paid in UK
U.S. President Donald Trump pledged to make prescription drugs cheaper for Americans than anywhere in the world, but his TrumpRx.gov website is not delivering across the board lower prices than those ...
Don't Miss This 14% Yield And This Pharma Value Stock
Trinity Capital offers a 14% yield, trading at a discount with a diversified, largely secured portfolio and steady NII outpacing dividends. Bristol Myers Squibb is executing a portfolio transition, wi...
Virtus Large Cap Growth SMA Q4 2025 Portfolio Review
The Silvant Large Cap Growth SMA returned +2.69% (gross)/+1.94% (net) for the quarter, outperforming the Russell 1000 Growth Index's return of +1.12%. Eli Lilly and Alphabet were among the top stock c...
Bristol Myers Squibb Announces Positive Phase 3 Results from the SUCCESSOR-2 Study of Oral Mezigdomide in Relapsed or Refractory Multiple Myeloma
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CELMoD--Bristol Myers Squibb Announces Positive Phase 3 Data from the SUCCESSOR-2 Study of Oral Mezigdomide in Relapsed or Refractory Multiple Myeloma.
U.S. FDA Approves Bristol Myers Squibb's Sotyktu® (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #FDA--U.S. FDA Approves Bristol Myers Squibb's Sotyktu® (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis.
February Dividends With 4 Raises: 1.6% Up To 14.5%
Rose's Income Garden portfolio reached an all-time high, with forward yield dipping slightly to 6% as portfolio value increased. Mastercard stands out with a 14.5% dividend raise, attractive valuation...
Bristol Myers Squibb Announces Dividend
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Announces Dividend.
Bristol-Myers Squibb Company (BMY) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Bristol-Myers Squibb Company (BMY) Presents at TD Cowen 46th Annual Health Care Conference Transcript
SystImmune and Bristol Myers Squibb Highlight Positive Phase III Interim Topline Results for izalontamab brengitecan (Iza-bren) in Previously Treated Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer
REDMOND, Wash. & PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Patients--SystImmune and BMS Highlight Positive Phase III Interim Topline Results for izalontamab brengitecan (Iza-bren) in Previously-Treat...
NYSE Content Update: Two MSCI Indexes to Begin Trading on NYSE Arca Options
NYSE issues a pre-market daily advisory direct from the trading floor. NEW YORK, Feb. 25, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the N...
Bristol Myers Squibb to Participate in the TD Cowen 46th Annual Health Care Conference
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Participate in the TD Cowen 46th Annual Health Care Conference.
Bristol Myers Squibb Announces Positive Top-Line Results from Registrational Phase 2 Study of Luspatercept in Adults with Alpha (α)-Thalassemia
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb Announces Positive Top-Line Results from Registrational Phase 2 Study of Luspatercept in Adults with Alpha (α)-Thalassemia.
Bristol-Myers: I'm Buying Post Earnings
Bristol-Myers: I'm Buying Post Earnings
Bristol-Myers Squibb: Oncology Franchise Remains A Core Strength
Bristol-Myers Squibb Company ended 2025 and started this year on a high note. On February 6, its stock reached a 52-week high of $63.3. One of the reasons BMY is once again becoming a Wall Street favo...
U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Iberdomide in Patients with Relapsed or Refractory Multiple Myeloma
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Iberdomide in Relapsed or Refractory Multiple Myeloma.
Best Stocks Outside The Mag 7 To Balance Growth And High Yield
Markets in 2026 are rewarding selectivity rather than size alone. Mega-cap leadership has narrowed, volatility has resurfaced, and investors are searching for a framework that can adapt to rotation. A...
Evinova and Bristol Myers Squibb Forge Strategic Collaboration to Optimize Clinical Development with Artificial Intelligence
BAAR, Switzerland--(BUSINESS WIRE)--Evinova and Bristol Myers Squibb Forge Strategic Collaboration to Optimize Clinical Development with Artificial Intelligence.
Bristol-Myers Squibb: A Dividend Gem With Hidden Upside In 2026
Bristol-Myers Squibb is upgraded to Buy as its growth portfolio now offsets legacy declines, validating a bullish contrarian thesis. BMY's 2026 guidance and Q4 2025 results exceeded consensus, with ma...
Bristol Myers Squibb CEO: Richest product pipeline we've had in the last decade
Chris Boerner, Bristol Myers Squibb CEO, joins CNBC's "Power Lunch" to discuss the company's quarterly earnings results, the drug pipeline and much more.